We are live on ! Find out more
TEVA icon

Teva Pharmaceuticals
TEVA

772 hedge funds and large institutions have $29.6B invested in Teva Pharmaceuticals in 2014 Q3 according to their latest regulatory filings, with 60 funds opening new positions, 254 increasing their positions, 309 reducing their positions, and 65 closing their positions.

New
Increased
Maintained
Reduced
Closed

128% more call options, than puts

Call options by funds: $1.34B | Put options by funds: $589M

14% more capital invested

Capital invested by funds: $26B → $29.6B (+$3.61B)

0.48% more ownership

Funds ownership: 52.26% → 52.74% (+0.48%)

1% less funds holding

Funds holding: 779 → 772 (-7)

8% less first-time investments, than exits

New positions opened: 60 | Existing positions closed: 65

4% less funds holding in top 10

Funds holding in top 10: 49 → 47 (-2)

18% less repeat investments, than reductions

Existing positions increased: 254 | Existing positions reduced: 309

Holders
772
Holders Change
-7
Holders Change %
-0.9%
% of All Funds
22.4%
Holding in Top 10
47
Holding in Top 10 Change
-2
Holding in Top 10 Change %
-4.08%
% of All Funds
1.36%
New
60
Increased
254
Reduced
309
Closed
65
Calls
$1.34B
Puts
$589M
Net Calls
+$755M
Net Calls Change
-$241M

Top Buyers

Rank Fund Capital Flow
1
WRF
Waddell & Reed Financial
Kansas
+$376M
2
Boston Partners
Boston Partners
Massachusetts
+$259M
3
William Blair & Company
William Blair & Company
Illinois
+$246M
4
BA
BlackRock Advisors
Delaware
+$143M
5
SCM
Scopia Capital Management
New York
+$141M

Top Sellers

Rank Fund Capital Flow
1
Norges Bank
Norges Bank
Norway
-$500M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$164M
3
Bank of America
Bank of America
North Carolina
-$148M
4
Bank of New York Mellon
Bank of New York Mellon
New York
-$132M
5
PC
PointState Capital
New York
-$110M
Name Holding Trade Value Shares
Change 		Change in
Stake
UAS
626
United Asset Strategies
New York
$288K – – –
SI
627
SII Investments
Wisconsin
$288K +$7.95K +150 +3%
PCM
628
Perkins Capital Management
Minnesota
$285K – – –
WPW
629
Waldron Private Wealth
Pennsylvania
$278K -$43.5K -822 -14%
SIM
630
Strategic Investment Management
Virginia
$277K +$273K +5,160 New
FHC
631
First Heartland Consultants
Missouri
$272K – – –
RW
632
Rand Wealth
Maryland
$272K – – –
TWA
633
TCI Wealth Advisors
Arizona
$270K -$101K -1,908 -28%
SAS
634
Spectrum Advisory Services
Georgia
$269K – – –
HIM
635
Hillsdale Investment Management
Ontario, Canada
$269K +$265K +5,000 New
WKWM
636
Walter & Keenan Wealth Management
Indiana
$269K +$265K +5,000 New
VNA
637
VNBTrust National Association
Virginia
$268K – – –
FCM
638
Forester Capital Management
Illinois
$260K – – –
NAM
639
NTV Asset Management
West Virginia
$257K +$1.75K +33 +0.7%
CAM
640
Columbia Asset Management
Michigan
$251K – – –
OFS
641
Orrstown Financial Services
Pennsylvania
$250K +$246K +4,651 New
WCM
642
Weatherstone Capital Management
Colorado
$249K – – –
WTC
643
WhitTier Trust Company
Nevada
$247K +$2.65K +50 +1%
CCA
644
Checchi Capital Advisers
California
$244K – – –
SGAM
645
Smith Group Asset Management
Texas
$244K +$11K +208 +5%
DAS
646
Dynamic Advisor Solutions
Arizona
$244K +$240K +4,534 New
WP
647
WMS Partners
Maryland
$243K – – –
KFS
648
Kurt F. Somerville
$241K – – –
KCM
649
Kanawha Capital Management
Virginia
$237K – – –
EWM
650
Elite Wealth Management
Washington
$234K +$228K +4,300 +8,600%
24 25
26
27 28

TEVA Hedge Fund Activity: Q3 2014 in Review

772 of the 3,447 institutional investors tracked by Wall St. Rank reported a position in Teva Pharmaceuticals (TEVA) for Q3 2014, worth a combined $29.6B — up 14% from $26B a quarter earlier.

Sellers outnumbered buyers: 65 funds closed out of TEVA and 60 opened new positions — a net loss of 5 holders — while 309 trimmed existing stakes and 254 added.

The largest buyer was Waddell & Reed Financial, adding an estimated $376M. The largest seller was Norges Bank, cutting an estimated $500M.

  • 772 institutional investors held Teva Pharmaceuticals (TEVA) as of Q3 2014, down from 779 in Q2 2014.
  • Funds reported $29.6B of Teva Pharmaceuticals stock for Q3 2014, up 14% quarter-over-quarter.
  • 60 funds opened new Teva Pharmaceuticals positions in Q3 2014 and 65 closed out, a net change of -5 holders.
  • The largest Teva Pharmaceuticals buyer in Q3 2014 was Waddell & Reed Financial, an estimated $376M added.
  • The largest Teva Pharmaceuticals seller in Q3 2014 was Norges Bank, an estimated $500M sold.

Based on aggregated 13F filings for Q3 2014.